Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version between February and March 2025.
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...